Drugs / LY03015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07671833 | Apr → May 2026 | — | Luye Pharma Group Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Luye Pharma Group Ltd. | Results 绿叶制药创新药LY03015（VMAT2抑制剂/Sigma-1R激动剂）在美国成功完成桥接临床试验 luye.com ↗
该 研 究 证 实 了LY03015在 高 加 索 人 群 与 中 国 人 群 药 代 行 为 一 致，且 高 加 索 人 群 安 全 耐 受 性 更 优. |
| 2021-09-28 | Luye Pharma Group Ltd. | Results 绿叶制药新一代VMAT2抑制剂LY03015研究成果发表于《European Journal of Medicinal Chemistry》学术期刊 luye.com ↗
开 发 过 程 中，化 合 物13e（LY03015）表 现 出 比DTBZ更 显 著 的VMAT2结 合 亲 和 力（IC50=5.13 nM）； |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Luye Pharma Group Ltd. | 绿叶制药创新药LY03015（VMAT2抑制剂/Sigma-1R激动剂）在美国成功完成桥接临床试验 luye.com ↗ |
| 2021-09-28 | Luye Pharma Group Ltd. | 绿叶制药新一代VMAT2抑制剂LY03015研究成果发表于《European Journal of Medicinal Chemistry》学术期刊 luye.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY03015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07671833 ↗ |
| Known as | LPM3770164 | “LY03015 (LPM3770164) is an investigational extended-release tablet administered.” NCT07671833 ↗ |
| Action | Inhibit | “LY03015, a new generation dual-target drug is a selective VMAT2 inhibitor and sigma-1 receptor.” NCT07671833 ↗ |
| Route | Oral | “A single dose of 20 mg LY03015 will be administered orally under fasting condition.” NCT07671833 ↗ |